09 — Regulatory Guidances Index
Expert synthesis of all key regulatory documents governing ADC bioanalysis, nonclinical safety, clinical pharmacology, and immunogenicity assessment.
Navigation
| File | Agency | Document | Year | ADC Relevance |
|---|---|---|---|---|
| FDA_ADC_ClinPharm_2024.md | FDA | Clinical Pharmacology Considerations for ADCs | 2024 (Final) | ★★★★★ ADC-specific |
| ICH_M10_BMV_2022.md | ICH | Bioanalytical Method Validation (M10) | 2022 | ★★★★★ BMV standard |
| FDA_BMV_2018.md | FDA | Bioanalytical Method Validation | 2018 | ★★★★☆ US BMV baseline |
| FDA_Immunogenicity.md | FDA | Immunogenicity / ADA Assay Development | 2014 + 2019 | ★★★★☆ ADA testing |
| FDA_PopPK_2019.md | FDA | Population Pharmacokinetics | 2019 | ★★★★☆ popPK submissions |
| ICH_S9_oncology.md | ICH | Nonclinical Evaluation for Anticancer Pharmaceuticals (S9) | 2009 | ★★★★☆ Nonclinical tox |
| ICH_M3R2_S6R1.md | ICH | M3(R2) Study Timing + S6(R1) Biotech Safety | 2009 + 2011 | ★★★☆☆ IND package |
| EMA_MABEL_FIH.md | EMA | Strategies for FIH Trials / MABEL | 2018 (Rev.1) | ★★★★☆ FIH dose selection |
| EMA_ADC_ReflectionPaper.md | EMA | Reflection Paper on ADCs | Draft 2020 | ★★★★★ ADC-specific EU |
| AAPS_ADC_WhitePapers.md | AAPS/Industry | ADC Bioanalysis & Immunogenicity White Papers | 2013–2022 | ★★★★★ Industry consensus |
Regulatory Interaction Map for ADC Development
Discovery → Lead Optimization → IND-Enabling → FIH (Phase 1) → Phase 2 → Phase 3 → NDA/BLA
│ │ │ │ │
ICH S9 FDA FIH FDA BMV/ FDA BMV/ FDA ADC
ICH M3(R2) guidance ICH M10 ICH M10 ClinPharm
ICH S6(R1) EMA MABEL FDA Immuno FDA PopPK ICH M10
FDA Biomarker AAPS WPs AAPS WPs
Key Principle: ADC as a Dual-Nature Product
All regulatory guidances must be read through the lens of ADC’s dual nature:
- Antibody component → ICH S6(R1), ICH M3(R2), FDA S6(R1), EMA biotech guideline
- Cytotoxic payload component → ICH S9 (oncology), standard small molecule toxicology
- Conjugate as a whole → FDA ADC ClinPharm 2024, EMA Reflection Paper, AAPS white papers
No single guidance fully addresses an ADC — sponsors must triangulate across multiple documents.